



# REAL-WORLD EVIDENCE<sup>+</sup>

# REPAIR OF LARGE-BORE ARTERIAL ACCESS-SITES

A Comparison of Suture-Mediated Closure  
with Perclose<sup>™</sup> Systems vs. Surgical Cutdown

**Perclose<sup>™</sup> ProStyle<sup>™</sup>**  
Suture-Mediated Closure and Repair System

Sources can be found on page 6.

**Information contained herein for DISTRIBUTION outside of the U.S. ONLY. Check the regulatory status of the device in areas where CE marking is not the regulation in force.**

©2024 Abbott. All rights reserved. MAT-2401055 v1.0



## REAL-WORLD EVIDENCE†

This real-world clinical study was designed to compare clinical and economic outcomes and complication rates among patients undergoing closure of large-bore arterial access sites via suture-mediated repair using the Perclose™ Family of Products (Perclose) versus Surgical Cutdown (Cutdown) in a real-world setting.

- The Perclose™ Family of Products deliver a secure, non-masking percutaneous suture to the access site<sup>1</sup> that promotes primary healing<sup>2</sup> and has no reaccess restrictions.<sup>1</sup>
- This system has the broadest arterial and venous indication\*, and can be utilized for 5-21F<sup>1</sup>, (26F Max OD<sup>3</sup>) arterial sheaths and 5-24<sup>1</sup> (29F Max. OD<sup>3</sup>) venous sheaths.



Sources can be found on page 6.

**Information contained herein for DISTRIBUTION outside of the U.S. ONLY. Check the regulatory status of the device in areas where CE marking is not the regulation in force.**

©2024 Abbott. All rights reserved. MAT-2401055 v1.0

# DATABASE AND PATIENT POPULATION<sup>†§</sup>

A retrospective study utilizing IBM Explorys data from IBM Watson Health with longitudinal data for approximately **55 million U.S. patients**.


## PATIENT SELECTION AND METHODOLOGY:

- Matched cohorts<sup>4</sup>
- Multivariate regression controlled for baseline<sup>5</sup>

## PATIENT BASELINE:

	Cutdown	Perclose™ Systems
# of Patients	757	757
Anticoagulants <sup>◇</sup>	17.8%	44.9%

<sup>◇</sup>p<0.05



Patients may have had multiple procedures during index admission

Sources can be found on page 6.

**Information contained herein for DISTRIBUTION outside of the U.S. ONLY. Check the regulatory status of the device in areas where CE marking is not the regulation in force.**


©2024 Abbott. All rights reserved. MAT-2401055 v1.0

# KEY STUDY FINDINGS<sup>†§</sup>

The use of Perclose™ Systems is associated with significantly lower blood transfusions, infections, mortality, and hospital length of stay (LOS) compared to surgical cutdown.

## INDEX HOSPITALIZATION

Perclose™ patients **80%** less likely to require a blood transfusion and **41%** less likely to have an infection.




Outcome	Odds Ratio		p-value	Confidence Interval	
	Cutdown N=757	Perclose™ N=757		Lower	Upper
Blood Transfusion	1	0.20	<0.001	0.15	0.27
Infection	1	0.59	<0.001	0.44	0.79

■ Surgical Cutdown ■ Perclose™ Systems

## 30-DAYS

At 30 days, Perclose™ patients were **79%** less likely to require a blood transfusion, **43%** less likely to have an infection.



Outcome	Odds Ratio		p-value	Confidence Interval	
	Cutdown N=600	Perclose™ N=662		Lower	Upper
Blood Transfusion	1	0.21	<0.001	0.15	0.28
Infection	1	0.57	<0.001	0.44	0.73

Sources can be found on page 6.

**Information contained herein for DISTRIBUTION outside of the U.S. ONLY. Check the regulatory status of the device in areas where CE marking is not the regulation in force.**


©2024 Abbott. All rights reserved. MAT-2401055 v1.0

# KEY STUDY FINDINGS<sup>†</sup> (CONT.)

Patients in the Perclose™ cohort had a 42% shorter index hospitalization, which corresponded to US \$14,687 lower costs.

## MORTALITY\*\*


At 30 days, Perclose™ patients **70%** less likely to die.



Time point	Odds Ratio		p-value	Confidence Interval	
	Cutdown N=757	Perclose™ N=757		Lower	Upper
30-days	1	<b>0.30</b>	<0.001	0.13	0.71

## HOSPITALIZATION LENGTH OF STAY (LOS)\*\*\*

Hospitalization **42%** shorter for Perclose™ patients.



	Odds Ratio		p-value	Confidence Interval	
	Cutdown N=757	Perclose™ N=757		Lower	Upper
	1	<b>0.58</b>	<0.001	0.53	0.62

■ Surgical Cutdown    ■ Perclose™ Systems

Sources can be found on page 6.

**Information contained herein for DISTRIBUTION outside of the U.S. ONLY. Check the regulatory status of the device in areas where CE marking is not the regulation in force.**

©2024 Abbott. All rights reserved. MAT-2401055 v1.0

**This study was an Investigator Sponsored Study funded by Abbott.**

† Schneider, DB., Zvonimir, K., et al., Clinical and economic outcomes of ProGlide compared with surgical repair of large bore arterial access. *J. Comp. Eff. Res.* (2019) 8(16), 1381 -1392

§ Schneider, DB., Perclose ProGlide vs. Surgical Closure Outcomes - Real world Evidence (LINC 2018 Presentation)

\* As compared to Angio-Seal‡, ExoSeal‡, FemoSeal‡, InClosure‡, MANTA‡, Mynx‡, PerQseal‡, Vascade‡, Velox CD‡, X-Seal‡. Data on file at Abbott.

\*\* Logistical regression model performed for mortality.

\*\*\* Poisson regression model performed for hospital length of stay.

1. Perclose ProGlide™ SMC System and Perclose™ ProStyle™ SMCR System – Instructions for Use (IFU). Refer to IFU for additional information.
2. Primary intention healing occurs where vessel wall edges are brought together, adjacent to each other. This can be achieved with suture, stitches, staples and clips. Advances in Skin & Wound Care: Healing by Intention. Salcido, Richard. 2017
3. Data on file at Abbott.
4. Age, Sex, Index procedure, Index year, Baseline blood transfusion, Peripheral vascular disease.
5. Anticoagulant use, Atherosclerosis, Cancer, Chronic respiratory disease, MI, Stroke, Blood transfusion.

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at [vascular.eifu.abbott](http://vascular.eifu.abbott) or at [medical.abbott/manuals](http://medical.abbott/manuals) for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events. This material is intended for use with healthcare professionals only.

**Information contained herein for DISTRIBUTION outside of the U.S. ONLY.**  
**Check the regulatory status of the device in areas where CE marking is not the regulation in force.**

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.

**Abbott International BVBA**

Park Lane, Culliganlaan 2B, 1831 Diegem, Belgium, Tel: 32.2.714.14.11

™ Indicates a trademark of the Abbott Group of Companies.

‡ Indicates a third-party trademark, which is property of its respective owner.

[www.cardiovascular.abbott](http://www.cardiovascular.abbott)

©2024 Abbott. All rights reserved. MAT-2401055 v1.0

